<DOC>
	<DOCNO>NCT01530711</DOCNO>
	<brief_summary>Observe effect terlipressin renal function patient SHR type I adjust dose base hemodynamic response .</brief_summary>
	<brief_title>Treatment Hepatorenal Syndrome With Terlipressin Infusion Adjusted Hemodynamic Response</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>Patients hepatorenal syndrome type 1 . Signed informed consent . No exclusion criterion . At least 18 year old Negative pregnancy test serum urine woman childbearing age , agree use adequate contraception since least 14 day prior first dose study drug 14 day last . Hepatocellular carcinoma : exclusion patient hepatocellular carcinoma present 3 nodule , single nodule large 5 cm , tumor portal thrombosis extrahepatic tumor spread . Active bacterial infection symptom systemic inflammatory response ( fever , tachycardia , tachypnea , hypotension , septic blood count ) . Cardiac respiratory failure clinically significant . Clinically significant peripheral artery disease . A history ischemic heart disease . Hypersensitivity terlipressin / albumin excipients . Pregnancy . Septic shock . Chronic renal failure . Women lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>